Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Paresthesia × 2,2'-dithiodiethanesulfonic acid × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Paresthesia 1 Neurotoxicity Syndromes 1 Neoplasms 1 Neoplasm Metastasis 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Breast Diseases 1

Interventions

xaliproden 2 Polyamines 1 Oxaliplatin 1 Leucovorin 1 Fluorouracil 1 2,2'-dithiodiethanesulfonic acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00039780 2022-07-13

Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel

BioNumerik Pharmaceuticals, Inc.

Phase 3 Completed

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Paresthesia, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon ⚡